**Shares of drugmaker Arcutis Biotherapeutics ARQT.O rise 12.9% to $16.91

** Co says it has agreed to temporarily pause a patent lawsuit with Israel-based Padagis regarding the latter attempting to produce a generic version of ARQT's Zoryve

** Zoryve is used to treat skin disorders including plaque psoriasis, seborrheic dermatitis and atopic dermatitis

** As part of the agreement, Padagis will keep Arcutis updated on any communication with the FDA about their generic version of Zoryve

** The patent for Zoryve is protected until at least 2037

** Including session's moves, ARQT stock up 19.4% YTD

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))